-- Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second ...
Vigil Neuroscience reported positive Phase 1 trial results for VG-3927 and plans a Phase 2 trial in Q3 2025. Vigil Neuroscience, Inc. announced promising outcomes from a Phase 1 clinical trial of ...
Encouraging anti-tumour activity seen across all dose levels and in various tumour indications Clinical benefit rate of 80% for 10 patients with HER2+ oesophageal cancer who had received prior therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback